A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
A phase 2 trial of Acitretin and Vemurafenib in Melanoma, run by University of Arizona, recorded as terminated on the registry.
Overview
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma is a phase 2 interventional study registered as NCT02050321 by University of Arizona, with 2 participants recorded, started 2013-12 and due to reach its primary completion in 2014-12. Interventions recorded: Acitretin, Vemurafenib. Conditions recorded: Malignant Melanoma.
Linked to the drug Acitretin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialPhase II Trial of Ontak With Metastatic Melanoma
Shares Melanoma and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialSafety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialSafety and Efficacy of OBX-115 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialAn Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
Shares Melanoma and the tag pipeline.
- TrialOH2 Injection in Melanoma
Shares Melanoma and the tag pipeline.
- TrialDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Shares Melanoma and the tag pipeline.